At a CSM(B) meeting, the Sub-Committee was informed that the manufacturer of Kryobulin PL/0215/0003 had not been visited recently, but the licensing authority intended to ask the Austrian authorities to carry out an inspection.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Duncan P Thomas